JAZZ News and Press, Jazz Pharmaceuticals plc From 05/11/20

DUBLIN , May 11, 2020 /PRNewswire/ --   Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America , effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly...

For years, Jazz Pharmaceuticals ' (NASDAQ: JAZZ) success has been almost entirely dependent on that of Xyrem, a narcolepsy drug responsible for more than 70% of the company's revenue. The company's good fortune is likely to come to an end: Recently, Harmony Biosciences ,  Avadel Pharmac...

DUBLIN , May 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: BofA Securities Virtual Healthcare Conference on Tuesday, May 12, 2020 at 3:00 ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2020 Q1 earnings Read more ...

Image source: The Motley Fool. Jazz Pharmaceuticals   (NASDAQ: JAZZ) Q1 2020 Earnings Call May 05, 2020 , 4:30 p.m. ET Operator Continue reading

Jazz Pharmaceuticals (NASDAQ: JAZZ) ended 2019 on a positive note, with shares up 20%. This year has been disastrous, though. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some.  The drugmaker announced its first-quarter results after the market closed on ...

Jazz Pharmaceuticals plc (JAZZ) Q1 2020 Earnings Conference Call May 05, 2020 04:30 PM ET Company Participants Kathy Littrell - Head of Investor Relations Bruce Cozadd - CEO Dan Swisher - President Renee Gala - CFO Rob Iannone - Executive Vice President, R&D Mike Mille...

Gainers: MELI   +18.9% .   VAPO   +15.9% . CLW   +10.0% . NTNX   +10.0% . AXNX   +9.2% . More news on: MercadoLibre, Inc., Vapotherm, Inc., Clearwater Paper Corporation, Stocks on the move, , Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q1 results : More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $0.45 misses by $0.38 ; GAAP EPS of -$2.82 misses by $1.72 . Revenue of $534.73M (+5.2% Y/Y) misses by $9.82M . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,